Cancer
Malignant Prostate Neoplasm
CI-CAN-00005927Explore in graph →
Top-level1,377 active trials24 approved drugs58 evidence items
- NCIt
- C7378
- ICD-10
- C61
- DOID
- 10283
- Other
- 2 more codes
Loading cancer entity…
Cancer
CI-CAN-00005927Explore in graph →
Clinical trials
5,979 studies whose conditions map to this entity or one of its descendants. Status and phase are as posted on ClinicalTrials.gov. 50 studies per page.
Computedformula ci-trial-intel-v1 · interventional studies · entity + NCIt descendants · hover a figure for its formulaCompare cancersTerminated studies (730)
| NCT | Title | Status | Phase | Enrollment (n) | Sponsor | Countries | Last update | Source |
|---|---|---|---|---|---|---|---|---|
| NCT06625970 | Study Evaluating the Efficacy and Safety of Darolutamide and Stereotactic Dose Escalated Radiotherapy in Patients With Localized Prostate Cancer and High-risk Features of Relapse(PEACE 7) | recruiting | Phase 3 | 700 | UNICANCEROTHER | 2 | Jul 31, 2026 | clinicaltrials |
| NCT03031821 | Metformin in Patients Initiating ADT as Prevention and Intervention of Metabolic Syndrome(PRIME) | terminated | Phase 3 | 166 | Canadian Urologic Oncology GroupOTHER |
| 1 |
| Jul 29, 2026 |
| clinicaltrials |
| NCT04484818 | Testing the Addition of Darolutamide to Hormonal Therapy (Androgen Deprivation Therapy [ADT]) After Surgery for Men With High-Risk Prostate Cancer, The ERADICATE Study | active not recruiting | Phase 3 | 27 | ECOG-ACRIN Cancer Research GroupNETWORK | 1 | Jul 28, 2026 | clinicaltrials |
| NCT02303327 | Comparative Study of Radiotherapy Treatments to Treat High Risk Prostate Cancer Patients | active not recruiting | Phase 3 | 307 | Sir Mortimer B. Davis - Jewish General HospitalOTHER | 1 | Jul 23, 2026 | clinicaltrials |
| NCT07052214 | PSMA PET Combined With MRI for the Detection of PCa(BiPASS) | recruiting | Phase 3 | 338 | Telix Pharmaceuticals (Innovations) Pty LimitedINDUSTRY | 2 | Jul 23, 2026 | clinicaltrials |
| NCT07641855 | A Study of BL-B01D1 Combination Therapy in Patients With Metastatic Castration-resistant Prostate Cancer | not yet recruiting | Phase 2 / Phase 3 | 180 | Sichuan Baili Pharmaceutical Co., Ltd.INDUSTRY | 1 | Jul 23, 2026 | clinicaltrials |
| NCT06520345 | The Study of 177Lu-TLX591 Plus SOC Versus SOC Alone in Patients With mCRPC (ProstACT Global) | recruiting | Phase 3 | 520 | Telix Pharmaceuticals (Innovations) Pty LimitedINDUSTRY | 6 | Jul 21, 2026 | clinicaltrials |
| NCT07426055 | PRO-BOOST-LC: Whole-Gland Boost Strategies Versus SBRT Monotherapy in PSMA-Staged Localized and Locally Advanced Prostate Cancer(PRO-BOOST-LC) | recruiting | Phase 2 / Phase 3 | 1,000 | Affidea Nu-med Center of Oncological DIagnostics and TherapyOTHER | 1 | Jul 21, 2026 | clinicaltrials |
| NCT07426094 | PRO-BOOST-N: Prostate-First Versus Combined Prostate and Nodal Dose Escalation in PSMA PET-Staged Node-Positive Prostate Cancer(PRO-BOOST-N) | recruiting | Phase 2 / Phase 3 | 600 | Affidea Nu-med Center of Oncological DIagnostics and TherapyOTHER | 1 | Jul 21, 2026 | clinicaltrials |
| NCT06592924 | Docetaxel to Androgen Receptor Pathway Inhibitors in Patients With Metastatic Castration Sensitive Prostate Cancer and Suboptimal PSA Response(TRIPLE-SWITCH) | recruiting | Phase 3 | 830 | Canadian Cancer Trials GroupNETWORK | 4 | Jul 14, 2026 | clinicaltrials |
| NCT02319837 | Safety and Efficacy Study of Enzalutamide Plus Leuprolide in Patients With Nonmetastatic Prostate Cancer (EMBARK) | active not recruiting | Phase 3 | 1,068 | PfizerINDUSTRY | 17 | Jul 9, 2026 | clinicaltrials |
| NCT03274687 | Hypofractionated Radiation Therapy or Conventional Radiation Therapy After Surgery in Treating Patients With Prostate Cancer | completed | Phase 3 | 296 | NRG OncologyOTHER | 3 | Jul 9, 2026 | clinicaltrials |
| NCT02692105 | Comparison of HDR vs. LDR Brachytherapy as Monotherapy for Intermediate Risk Prostate Cancer | active not recruiting | Phase 3 | 60 | British Columbia Cancer AgencyOTHER | 1 | Jun 29, 2026 | clinicaltrials |
| NCT07574489 | Whole Versus Partial Gland Boost During Prostate SBRT | not yet recruiting | Phase 2 / Phase 3 | 186 | University of NebraskaOTHER | 1 | Jun 29, 2026 | clinicaltrials |
| NCT00942331 | Gemcitabine Hydrochloride and Cisplatin With or Without Bevacizumab in Treating Patients With Advanced Urinary Tract Cancer | completed | Phase 3 | 506 | National Cancer Institute (NCI)NIH | 2 | Jun 24, 2026 | clinicaltrials |
| NCT06625034 | Radiation Therapy With RapidPlan Knowledge-based Planning vs Human-Driven Planning for Treatment of Prostate Cancer | recruiting | Phase 3 | 108 | Mayo ClinicOTHER | 1 | Jun 18, 2026 | clinicaltrials |
| NCT07477626 | Radiotherapy After Prostatectomy for Node Positive Prostate Cancer(RADVAN) | recruiting | Phase 3 | 372 | Sun Yat-sen UniversityOTHER | 1 | Jun 16, 2026 | clinicaltrials |
| NCT03769766 | Trial of Curcumin to Prevent Progression of Low-risk Prostate Cancer Under Active Surveillance | recruiting | Phase 3 | 291 | University of Texas Southwestern Medical CenterOTHER | 1 | Jun 15, 2026 | clinicaltrials |
| NCT05597878 | Opioid-Free Pain Control Regimen Following Robotic Radical Prostatectomy | terminated | Phase 2 / Phase 3 | 58 | Wake Forest University Health SciencesOTHER | 1 | Jun 15, 2026 | clinicaltrials |
| NCT05605964 | Randomized Study to Evaluate MACE in Patients With Prostate Cancer Treated With Relugolix or Leuprolide Acetate | completed | Phase 3 | 387 | Sumitomo Pharma America, Inc.INDUSTRY | 1 | Jun 15, 2026 | clinicaltrials |
| NCT03348670 | Pharmacogenomics IND Commercial SNP Clinical Study - Abiraterone and Single Nucleotide Polymorphisms(Drugs-SNPs) | active not recruiting | Phase 2 / Phase 3 | 600 | Han Xu, M.D., Ph.D., FAPCR, Sponsor-Investigator, IRB ChairINDUSTRY | 1 | Jun 10, 2026 | clinicaltrials |
| NCT07632690 | QLC5508 in Participants With Metastatic Prostate Cancer | not yet recruiting | Phase 3 | 700 | Qilu Pharmaceutical Co., Ltd.INDUSTRY | 0 | Jun 8, 2026 | clinicaltrials |
| NCT06112990 | Creatine Supplementation and Resistance Training to Preserve Muscle Mass and Attenuate Cancer Progression(CREATINE-52) | recruiting | Phase 3 | 200 | University of UtahOTHER | 1 | Jun 3, 2026 | clinicaltrials |
| NCT06825091 | Is Adaptive SBRT for Prostate vs Image-guided Radiotherapy a True Evolution (ASPIRE)(ASPIRE) | recruiting | Phase 3 | 320 | University Health Network, TorontoOTHER | 1 | Jun 2, 2026 | clinicaltrials |
| NCT06851663 | Trop2-targeted immunoPET Imaging of Solid Tumors | recruiting | Phase 2 / Phase 3 | 400 | RenJi HospitalOTHER | 1 | May 29, 2026 | clinicaltrials |
| NCT03582774 | Multicenter Randomized Trial of 68Ga-PSMA-11 PET/CT Based SRT After Radical Prostatectomy(PSMA SRT) | active not recruiting | Phase 3 | 193 | Jonsson Comprehensive Cancer CenterOTHER | 1 | May 26, 2026 | clinicaltrials |
| NCT04263025 | AMNIOX CORD Study - Radical Prostatectomy With and Without Cryopreserved Umbilical Cord Allograft | active not recruiting | Phase 2 / Phase 3 | 100 | Hackensack Meridian HealthOTHER | 1 | May 26, 2026 | clinicaltrials |
| NCT02799706 | Trial Comparing Irradiation Plus Long Term Adjuvant Androgen Deprivation With GnRH Antagonist Versus GnRH Agonist Plus Flare Protection in Patients With Very High Risk Localized or Locally Advanced Prostate Cancer(PEGASUS) | active not recruiting | Phase 3 | 885 | European Organisation for Research and Treatment of Cancer - EORTCNETWORK | 8 | May 22, 2026 | clinicaltrials |
| NCT07427043 | Robotic Opioid-free Prostatectomy Enhanced Strategy (ROPES)(ROPES) | recruiting | Phase 3 | 300 | Brigham and Women's HospitalOTHER | 1 | May 22, 2026 | clinicaltrials |
| NCT03987386 | Conventional or Hypofractionated Radiation Therapy in Treating Patients With Prostate Cancer | active not recruiting | Phase 3 | 186 | M.D. Anderson Cancer CenterOTHER | 1 | May 20, 2026 | clinicaltrials |
| NCT07598032 | Comparative Analysis of Immunological Responses to Vitamin D Replacement Therapy in Black and West African Men Diagnosed With Prostate Cancer: Elucidating Differential Effects on Immune Function Between Patients With Localized Disease and Those With Metastatic Progression(iCCaRE) | not yet recruiting | Phase 3 | 200 | University of Ilorin Teaching HospitalOTHER | 1 | May 20, 2026 | clinicaltrials |
| NCT06691984 | Phase 3 Study of Xaluritamig vs Cabazitaxel or Second Androgen Receptor-Directed Therapy in Participants With Progressive Metastatic Castration-Resistant Prostate Cancer (XALute) | active not recruiting | Phase 3 | 707 | AmgenINDUSTRY | 22 | May 15, 2026 | clinicaltrials |
| NCT07591467 | Carboplatin-Enhanced Therapy in BRCA-Mutated or Neuroendocrine-Differentiated Aggressive Metastatic Castration-Sensitive Prostate Cancer(CaBRA) | not yet recruiting | Phase 3 | 330 | Gustave Roussy, Cancer Campus, Grand ParisOTHER | 1 | May 15, 2026 | clinicaltrials |
| NCT03574571 | A Study to Test Radium-223 With Docetaxel in Patients With Prostate Cancer | active not recruiting | Phase 3 | 732 | Memorial Sloan Kettering Cancer CenterOTHER | 4 | May 14, 2026 | clinicaltrials |
| NCT06970847 | 64Cu-SAR-bisPSMA Positron Emission Tomography: A Phase 3 Study of Participants With Biochemical Recurrence of Prostate Cancer(AMPLIFY) | active not recruiting | Phase 3 | 220 | Clarity Pharmaceuticals LtdINDUSTRY | 2 | May 14, 2026 | clinicaltrials |
| NCT01368588 | Androgen-Deprivation Therapy and Radiation Therapy in Treating Patients With Prostate Cancer | active not recruiting | Phase 3 | 2,590 | Radiation Therapy Oncology GroupNETWORK | 6 | May 8, 2026 | clinicaltrials |
| NCT03819101 | Trial of Acetylsalicylic Acid and Atorvastatin in Patients With Castrate-resistant Prostate Cancer(PEACE-4) | recruiting | Phase 3 | 1,210 | Gustave Roussy, Cancer Campus, Grand ParisOTHER | 6 | May 6, 2026 | clinicaltrials |
| NCT04136353 | Darolutamide Augments Standard Therapy for Localised Very High-Risk Cancer of the Prostate(DASL-HiCaP) | active not recruiting | Phase 3 | 1,100 | University of SydneyOTHER | 6 | May 6, 2026 | clinicaltrials |
| NCT03772834 | Methylphenidate and Exercise in Reducing Cancer-Related Fatigue in Patients With Prostate Cancer | active not recruiting | Phase 2 / Phase 3 | 200 | M.D. Anderson Cancer CenterOTHER | 1 | May 4, 2026 | clinicaltrials |
| NCT04261777 | Ferumoxtran-10-enhanced MRI in Prostate Cancer Patients | terminated | Phase 3 | 172 | Saving Patients' Lives Medical B.V.INDUSTRY | 4 | Apr 28, 2026 | clinicaltrials |
| NCT06439225 | Platinum and Taxane Chemo in Met Castration Resistant Prostate Cancer Patients With Alterations in DNA Damage Response Genes(OPTION-DDR) | recruiting | Phase 3 | 236 | Canadian Cancer Trials GroupNETWORK | 1 | Apr 16, 2026 | clinicaltrials |
| NCT06122584 | Diagnostic Performance of [18F]PSMA-1007 PET/CT Imaging in Patients With Newly-Diagnosed Prostate Cancer | recruiting | Phase 3 | 380 | ABX advanced biochemical compounds GmbHINDUSTRY | 6 | Apr 14, 2026 | clinicaltrials |
| NCT06235697 | Androgen Suppression Combined With Nodal Irradiation and Dose Escalated Prostate Treatment(ASCENDE-SBRT) | recruiting | Phase 3 | 710 | Canadian Cancer Trials GroupNETWORK | 2 | Apr 14, 2026 | clinicaltrials |
| NCT04787744 | Veterans Affairs Seamless Phase II/III Randomized Trial of STAndard Systemic theRapy With or Without PET-directed Local Therapy for Oligometastatic pRosTate Cancer(VA STARPORT) | recruiting | Phase 2 / Phase 3 | 464 | VA Office of Research and DevelopmentFED | 1 | Apr 8, 2026 | clinicaltrials |
| NCT02044354 | Patient Preference Between Cabazitaxel and Docetaxel in Metastatic Castrate-resistant Prostate Cancer(CABA-DOC) | completed | Phase 3 | 195 | Gustave Roussy, Cancer Campus, Grand ParisOTHER | 1 | Apr 1, 2026 | clinicaltrials |
| NCT02064673 | Adjuvant Curcumin to Assess Recurrence Free Survival in Patients Who Have Had a Radical Prostatectomy | recruiting | Phase 3 | 650 | yair lotanOTHER | 1 | Mar 30, 2026 | clinicaltrials |
| NCT07500701 | Salvage Moderate Hypofractionated Versus Ultrahypofractionated Radiotherapy for Biochemical Recurrence After Radical Prostatectomy in Prostate Cancer | recruiting | Phase 3 | 270 | Samsung Medical CenterOTHER | 1 | Mar 30, 2026 | clinicaltrials |
| NCT05678322 | Optimizing Timing of rhPSMA-7.3 (18F) for Assessing Site(s) of Recurrent Disease Following Radical Prostatectomy | active not recruiting | Phase 3 | 26 | NYU Langone HealthOTHER | 1 | Mar 25, 2026 | clinicaltrials |
| NCT03594760 | PSMA-PET: Deep Radiomic Biomarkers of Progression and Response Prediction in Prostate Cancer | recruiting | Phase 3 | 1,000 | Centre hospitalier de l'Université de Montréal (CHUM)OTHER | 1 | Mar 19, 2026 | clinicaltrials |
Data updated 22 days agoSource updated Jul 31, 2026source: clinicaltrials